As billionaires chase immortality, this startup cofounded by a Harvard genetics professor gets FDA approval for the first partial de-aging human trial.

The article discusses Life Biosciences, a biotech startup co-founded by Harvard geneticist David Sinclair, which has received FDA approval for a Phase 1 clinical trial of its gene therapy aimed at restoring vision in patients with eye conditions like glaucoma and non-arteritic anterior ischemic optic neuropathy (NAION). The therapy utilizes "partial epigenetic reprogramming" to rejuvenate damaged retinal ganglion cells, potentially reversing vision loss. The company plans to enroll patients soon, with results expected by early next year. Life Biosciences is taking a targeted approach to address optic neuropathies before expanding its research to other age-related conditions, reflecting the growing interest and investment in longevity science. [Extracted from the article]